BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34050668)

  • 1. Assessment of intra-sample variability in HIV-1 DNA drug resistance genotyping.
    Millière L; Bocket L; Tinez C; Robineau O; Veyer N; Wojciechowski F; Lambert V; Meybeck A; Huleux T; Ajana F; Hober D; Alidjinou EK
    J Antimicrob Chemother; 2021 Jul; 76(8):2143-2147. PubMed ID: 34050668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
    Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
    J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance.
    Raymond S; Nicot F; Abravanel F; Minier L; Carcenac R; Lefebvre C; Harter A; Martin-Blondel G; Delobel P; Izopet J
    J Clin Virol; 2020 Jan; 122():104229. PubMed ID: 31809945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of an
    Tzou PL; Ariyaratne P; Varghese V; Lee C; Rakhmanaliev E; Villy C; Yee M; Tan K; Michel G; Pinsky BA; Shafer RW
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical Assessment of the Vela Diagnostics NGS Assay for HIV Genotyping and Resistance Testing: The Apulian Experience.
    Bonifacio MA; Genchi C; Lagioia A; Talamo V; Volpe A; Mariggiò MA
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing.
    Weber J; Volkova I; Sahoo MK; Tzou PL; Shafer RW; Pinsky BA
    J Mol Diagn; 2019 Nov; 21(6):961-970. PubMed ID: 31382033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance.
    Van den Eede P; Van Wesenbeeck L; Verlinden Y; Feyaerts M; Smits V; Verheyen A; Vanhooren L; Deloof A; Villacian J; Pattery T
    Methods Mol Biol; 2013; 1030():37-55. PubMed ID: 23821259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
    Raymond S; Nicot F; Carcenac R; Lefebvre C; Jeanne N; Saune K; Delobel P; Izopet J
    J Antimicrob Chemother; 2018 May; 73(5):1152-1157. PubMed ID: 29444253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals.
    Shafer RW; Warford A; Winters MA; Gonzales MJ
    J Virol Methods; 2000 May; 86(2):143-53. PubMed ID: 10785289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
    Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
    J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16.
    Mbunkah HA; Marzel A; Schmutz S; Kok YL; Zagordi O; Shilaih M; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Kouyos RD; Günthard HF; Metzner KJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1917-1929. PubMed ID: 29635462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).
    Montejano R; Dominguez-Dominguez L; de Miguel R; Rial-Crestelo D; Esteban-Cantos A; Aranguren-Rivas P; García-Álvarez M; Alejos B; Bisbal O; Santacreu-Guerrero M; Hernando A; Bermejo-Plaza L; Cadiñanos J; Mayoral M; Castro JM; Moreno V; Martin-Carbonero L; Rodés B; Delgado R; Rubio R; Pulido F; Arribas JR
    J Antimicrob Chemother; 2021 Nov; 76(12):3263-3271. PubMed ID: 34459889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
    Wilson JW; Bean P; Robins T; Graziano F; Persing DH
    J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.